Supplementary Materials

Supplementary Material for:

Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice

Julie A. Moreno, Mark Halliday, Colin Molloy, Helois Radford, Nicholas Verity, Jeffrey M. Axten, Catharine A. Ortori, Anne E. Willis, Peter M. Fischer, David A. Barrett, Giovanna R. Mallucci*

*Corresponding author. E-mail: grm7@le.ac.uk

Published 9 October 2013, Sci. Transl. Med. 5, 206ra138 (2013)
DOI: 10.1126/scitranslmed.3006767

This PDF file includes:

  • Fig. S1. Schematic representation of UPR signaling leading to translational repression in prion disease and point of action of GSK2606414.
  • Fig. S2. Body weights of prion-infected mice treated with GSK2606414 and vehicle.
  • Fig. S3. Blood glucose levels in prion-infected mice treated with GSK2606414 and vehicle.
  • Fig. S4. Biochemical, morphological, and behavioral characterization of uninfected mice treated with GSK2606414.
  • Fig. S5. Additional synaptic protein levels in prion-infected mice treated with GSK2606414 and vehicle.
  • Movies S1 to S5 legend

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Movies S1 to S5 (.mpg format). GSK2606414 prevents clinical signs of prion disease in mice.

[Movies S1 to S5]